Clarivate (CLVT) to Release Quarterly Earnings on Wednesday

Clarivate (NYSE:CLVT) is anticipated to announce its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $0.17 per share and revenue of $589.7290 million for the quarter. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 9:30 AM ET.

Clarivate (NYSE:CLVT) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.04. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. The company had revenue of $585.50 million for the quarter, compared to analyst estimates of $569.50 million. During the same period in the prior year, the firm posted $0.14 EPS. The company’s quarterly revenue was down 1.4% on a year-over-year basis. On average, analysts expect Clarivate to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Clarivate Trading Down 0.2%

CLVT opened at $2.04 on Monday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 0.89. The stock has a market cap of $1.30 billion, a PE ratio of -9.69 and a beta of 1.38. The company has a fifty day moving average of $2.30 and a 200-day moving average of $2.46. Clarivate has a twelve month low of $1.66 and a twelve month high of $4.77.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CLVT. Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a research note on Wednesday, June 24th. Wall Street Zen raised Clarivate from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Barclays lifted their target price on Clarivate from $2.40 to $2.50 and gave the stock an “underweight” rating in a report on Tuesday, July 7th. Four investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $2.98.

Institutional Trading of Clarivate

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FIL Ltd boosted its holdings in Clarivate by 2.3% in the fourth quarter. FIL Ltd now owns 25,266,152 shares of the company’s stock worth $84,389,000 after acquiring an additional 567,170 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Clarivate by 3.3% during the third quarter. Dimensional Fund Advisors LP now owns 21,768,783 shares of the company’s stock valued at $83,373,000 after acquiring an additional 696,903 shares in the last quarter. Atairos Partners GP Inc. raised its position in shares of Clarivate by 195.3% during the fourth quarter. Atairos Partners GP Inc. now owns 10,232,667 shares of the company’s stock worth $34,177,000 after purchasing an additional 6,767,667 shares during the period. Vanguard Group Inc. raised its position in shares of Clarivate by 9.3% during the third quarter. Vanguard Group Inc. now owns 8,922,585 shares of the company’s stock worth $34,173,000 after purchasing an additional 756,722 shares during the period. Finally, State Street Corp lifted its holdings in shares of Clarivate by 0.4% in the 4th quarter. State Street Corp now owns 7,602,697 shares of the company’s stock worth $25,393,000 after purchasing an additional 30,933 shares in the last quarter. 85.72% of the stock is owned by institutional investors.

About Clarivate

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.